الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
The discovery of serum prostate specific antigen (PSA) and its extensive use for the last two decades has dramatically influenced the way prostate cancer is diagnosed and monitored both before and after treatment (1). In spite of this, limitations still exist in the use of the PSA screening for early detection of prostate cancer, which has led to conflicting recommendations regarding the target people for and the time of screening. Perhaps the most significant issue is the inability to determine a cut-point for “normal” PSA level, resulting in a relatively poor positive predictive value of the PSA screening test (2). Results from the end-of-study biopsies performed as part of the Prostate Cancer Prevention Trial (PCPT) indicate poor sensitivity at the PSA cut-point of 4.0 ng/mL and no normal threshold as clinically significant prostate cancer was discovered at all PSA levels (3). Findings from the San Antonio Center for Biomarkers Of Risk (SABOR) study were the first to demonstrate a strong inverse relation between body mass index (BMI) and total serum PSA level among a population-based sample of healthy men without prostate cancer, suggesting that reliance on PSA testing and the current recommended PSA cutoffs for men in the general population (≥4.0 ng/ml) for biopsy referral in obese men may result in protracted progression of disease (8). We have conducted a review of the recent literature published in the area of obesity and prostate specific antigen in an effort to synthesize the existing knowledge and discuss the impact of these findings in the context of current and future prostate cancer screening practices